文献速递淋巴瘤

抗PD1治疗经典霍奇金淋巴瘤:肿瘤与微环境应答但无细胞毒性T细胞活化

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
PubMed 文献 · Blood · 2020-01-01

该研究基于NIVAHL试验,分析nivolumab一线治疗早期预后不良经典霍奇金淋巴瘤患者配对活检和血样。结果显示首次用药后数天内Hodgkin和Reed-Sternberg细胞从组织消失,微环境中1型调节性T细胞和PD-L1阳性肿瘤相关巨噬细胞减少,但肿瘤和外周血均未观察到细胞毒性免疫应答及克隆性T细胞扩增。提示抗PD1在cHL中的早期作用机制可能是撤除促生存因子,而非诱导适应性抗肿瘤免疫应答。

要点

  • nivolumab首次给药后数天内Hodgkin和Reed-Sternberg细胞即从组织消失。
  • 微环境中1型调节性T细胞和PD-L1阳性肿瘤相关巨噬细胞早期减少。
  • 肿瘤和外周血均未观察到细胞毒性免疫应答或克隆性T细胞扩增。

核心结论

  • 抗PD1治疗cHL的早期组织学应答模式提示撤除促生存因子而非诱导适应性抗肿瘤免疫应答是主要作用机制。

研究设计与样本

  • 分析NIVAHL试验中接受nivolumab一线治疗的早期预后不良cHL患者治疗前及治疗最初数天的配对活检和血样。

主要发现

  • 首次nivolumab应用后数天内Hodgkin和Reed-Sternberg细胞从组织消失。
  • 治疗早期微环境中1型调节性T细胞和PD-L1阳性肿瘤相关巨噬细胞减少。
  • 肿瘤和外周血中未观察到细胞毒性免疫应答及克隆性T细胞扩增。
  • 这些早期微环境变化与抗PD1治疗复发时cHL活检中的改变不同。

临床怎么用

  • 提示抗PD1治疗cHL的早期疗效评估可能需关注肿瘤微环境变化而非细胞毒性T细胞活化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Classic Hodgkin lymphoma (cHL) is the cancer type most susceptible to antibodies targeting programmed cell death protein 1 (PD1) and is characterized by scarce Hodgkin and Reed-Sternberg cells (HRSCs), perpetuating a unique tumor microenvironment (TME). Although anti-PD1 effects appear to be largely mediated by cytotoxic CD8+ T cells in solid tumors, HRSCs frequently lack major histocompatibility complex expression, and the mechanism of anti-PD1 efficacy in cHL is unclear. Rapid clinical responses and high interim complete response rates to anti-PD1 based first-line treatment were recently reported for patients with early-stage unfavorable cHL treated in the German Hodgkin Study Group phase 2 NIVAHL trial. To investigate the mechanisms underlying this very early response to anti-PD1 treatment, we analyzed paired biopsies and blood samples obtained from NIVAHL patients before and during the first days of nivolumab first-line cHL therapy. Mirroring the rapid clinical response, HRSCs had disappeared from the tissue within days after the first nivolumab application. The TME already shows a reduction in type 1 regulatory T cells and PD-L1+ tumor-associated macrophages at this early time point of treatment. Interestingly, a cytotoxic immune response and a clonal T-cell expansion were not observed in the tumors or peripheral blood. These early changes in the TME were distinct from alterations found in a separate set of cHL biopsies at relapse during anti-PD1 therapy. We identify a unique very early histologic response pattern to anti-PD1 therapy in cHL that is suggestive of withdrawal of prosurvival factors, rather than induction of an adaptive antitumor immune response, as the main mechanism of action.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Reinke S, Bröckelmann PJ, Iaccarino I, et al. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. Blood. 2020. PMID: 33113552. doi:10.1182/blood.2020008553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。